通宣理肺胶囊联合常规西药治疗急性支气管炎临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R562.2+1

基金项目:


Clinical Study on Tongxuan Lifei Capsules Combined with Routine Western Medicine for Acute Bronchitis
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察通宣理肺胶囊联合常规西药治疗急性支气管炎的临床疗效。方法:将92 例急性支气管炎患者随机分为对照组与观察组各46 例。对照组予以布地奈德、异丙托溴铵、特布他林联合治疗,观察组在对照组的基础上予以通宣理肺胶囊治疗。比较2 组症状积分、症状体征(发热、喘息、咳嗽、哮鸣音) 消失时间与住院时间、肺功能指标[用力肺活量(FVC)、第1 秒用力呼气容积(FEV1)、FEV1/FVC]、炎症因子[C-反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)]水平及总体临床疗效。结果:观察组总有效率为95.65%,对照组为78.26%,2 组比较,差异有统计学意义(P<0.05)。治疗后,2 组喘憋气促、咳嗽咳痰、烦躁不安、舌红苔黄、脉滑数积分均较治疗前降低(P<0.05),且观察组各项症状积分均低于对照组(P<0.05)。治疗后,观察组症状体征消失时间、住院治疗时间均短于对照组,差异均有统计学意义(P<0.05)。治疗后,2 组FVC、FEV1、FEV1/FVC 等指标均较治疗前升高(P<0.05),且观察组各项指标均高于对照组(P<0.05)。治疗后,2 组血清CRP、IL-6、IL-8 水平均较治疗前降低(P<0.05),且观察组CRP、IL-6、IL-8 水平均低于对照组(P<0.05)。结论:通宣理肺胶囊联合常规西药治疗急性支气管炎可提高疗效,缓解临床症状,减轻炎症反应,改善肺功能。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Tongxuan Lifei capsules combined with routine western medicine for acute bronchitis. Methods:A total of 92 cases of patients with acute bronchitis were selected and randomly divided into the control group and the observation group,with 46 cases in each group. The control group was treated with budesonide, ipratropium bromide and terbutaline,and the observation group was additionally treated with Tongxuan Lifei capsules based on the treatment of the control group. Symptom scores,the disappearance time of symptoms and signs(fever,wheezing, cough, wheezing rales), hospitalization time, indexes of the lung function[forced vital capacity(FVC), forced expiratory volume in one second(FEV1), (FEV1/FVC)], levels of inflammatory factors[C- reactive protein(CRP), interleukin- 6(IL- 6), interleukin-8(IL-8)] and total clinical effects were compared between the two groups. Results:The total effective rate was 95.65% in the observation group, and 78.26% in the control group, the difference being significant(P<0.05). After treatment,scores of wheezing and panting,cough and expectoration,vexation and agitation,red tongue and yellow fur, and slippery and rapid pulse in the two groups were decreased when compared with those before treatment(P<0.05),and each score in the observation group was lower than that in the control group(P<0.05). After treatment,the disappearance time of symptoms and signs and hospitalization time in the observation group were shorter than those in the control group, differences being significant(P<0.05). After treatment, indexes of FVC, FEV1, and FEV1/FVC in the two groups were increased when compared with those before treatment(P<0.05),and each index in the observation group was higher than that in the control group(P<0.05). After treatment,levels of CRP,IL-6 and IL-8 in serum in the two groups were decreased when compared with those before treatment(P<0.05),and each level in the observation group was lower than that in the control group(P<0.05). Conclusion: The therapy of Tongxuan Lifei capsules combined with routine western medicine for acute bronchitis can improve the clinical effect and the lung function, and effectively relieve clinical symptoms and inflammatory responses.

    参考文献
    相似文献
    引证文献
引用本文

韩冬谊,陈淳,周明倩.通宣理肺胶囊联合常规西药治疗急性支气管炎临床研究[J].新中医,2022,54(4):57-60

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-02-24
  • 出版日期: